Rituximab-induced changes in hematolymphoid tissues found at autopsy

American Journal of Clinical Pathology

Volumn 130, Issue 4, 2008, Pages 604-612

  Cioc, Adina M ^a,b   Vanderwerf, Steven M ^a   Peterson, Bruce A ^a   Robu, Valentin G ^a   Forster, Colleen L ^a   Pambuccian, Stefan E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Autopsy; Immunohistochemistry; Lymph node; Rituximab; Spleen

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ARTICLE; AUTOPSY; B LYMPHOCYTE; CAUSE OF DEATH; DRUG EFFECT; HISTOPATHOLOGY; HUMAN; IMMUNOPEROXIDASE STAINING; LYMPHOCYTE SUBPOPULATION; LYMPHOID TISSUE; LYMPHOMA; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; ADOLESCENT; ADULT; B CELL LYMPHOMA; CHILD; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; MIDDLE AGED; SPLEEN;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPSY; B-LYMPHOCYTES; CHILD; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDNISONE; SPLEEN; VINCRISTINE;

EID: 54049117626     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/UXLE9RHL968TER7B     Document Type: Article

References (28)

1. Kosmas C, Stamatopoulos K, Stavroyianni N, et al. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 2002;16:2004-2015.
2. Sacchi S, Federico M, Dastoli G, et al. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody rituximab. Crit Rev Oncol Hematol. 2001;37:13-25.
3. Chu PG, Chen YY, Molina A, et al. Recurrent B-cell neoplasms after rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma. 2002;43:2335-2341.
4. Seliem RM, Freeman JK, Steingart RH, et al. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol. 2006;14:18-23.
5. Goteri G, Olivieri A, Ranaldi R, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol. 2006;19:421-431.
6. Cheung MC, Haynes AE, Meyer RM, et al. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev. 2007;33:161-176.
7. Turturro F. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival. Expert Rev Anticancer Ther. 2007;7:959-965.
8. Winter JN. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. Curr Opin Hematol. 2007;14:360-368.
9. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology. 2002;206:519-527.
10. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613-620.
11. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer. 2001;85:1619-1623.
12. Jaffe E, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:121-187. World Health Organization Classification of Tumours.
13. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
14. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127.
15. Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005;104:1661-1667.
16. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.
17. Garvin AJ, Simon RM, Osborne CK, et al. An autopsy study of histologic progression in non-Hodgkin's lymphomas: 192 cases from the National Cancer Institute. Cancer. 1983;52:393-398.
18. Ostrow S, Diggs CH, Sutherland J, et al. Causes of death in patients with non-Hodgkin's lymphoma. Cancer. 1981;48:779-782.
19. Risdall R, Hoppe RT, Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer. 1979;44:529-542.
20. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20: "what do B-cells do?" Clin Immunol. 2005;117:207-213.
21. Foran JM, Norton AJ, Micallef IN, et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001;114:881-883.
22. Chu PG, Loera S, Huang Q, et al. Lineage determination of CD20- B-cell neoplasms: an immunohistochemical study. Am J Clin Pathol. 2006;126:534-544.
23. Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol. 2002;119:412-416.
24. Loisel S, Ohresser M, Pallardy M, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol. 2007;62:34-42.
25. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
26. Schroder C, Azimzadeh AM, Wu G, et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19-28.
27. Vugmeyster Y, Beyer J, Howell K, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother. 2005;28:212-219.
28. Vugmeyster Y, Howell K, McKeever K, et al. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol. 2003;3:1477-1481.